Navigation Links
CareFusion Reports Fourth Quarter and Fiscal 2011 Results
Date:8/8/2011

SAN DIEGO, Aug. 8, 2011 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the quarter and fiscal year ended June 30, 2011.

"Growth in our Infusion, Dispensing and Infection Prevention businesses, gross margin expansion and the benefit of strong spending controls drove double digit improvements in our adjusted operating earnings for the quarter and for the year," said Kieran Gallahue, chairman and CEO. "We continue to make progress in optimizing our product portfolio and expanding our geographical footprint. We recently acquired pharmacy automation innovator Rowa, enabling us to expand our Pyxis platform outside the U.S."

"Looking ahead to fiscal 2012, we will continue to leverage operational efficiencies and reduce complexity across our businesses to drive bottom line growth that outpaces our top line growth. We are expecting revenue growth in a range of 3 to 5 percent over fiscal 2011 results, representing an improvement over the 2 percent growth we had this year and acceleration over the low single digit growth rates we are seeing in the markets where we participate. For adjusted EPS we are guiding to a range of $1.80 to $1.90."

CareFusion's reported results compare to the quarter and fiscal year periods ended June 30, 2010.

Results from the company's International Surgical Products (ISP) business, which had been included in the Medical Technologies and Services segment and was divested in April 2011, have been classified as discontinued operations in the accompanying financial tables. Reported results for continuing operations and comparisons to prior periods exclude the historical results of the ISP business.

Fourth Quarter ResultsRevenue for the fourth quarter of fiscal 2011 increased 4 percent to $964 million on a reported basis and 2 percent on a constant currency basis, driven primarily by increased sales in the Infusion, Dispensing and Infection Prevention businesses. Operating income was $149 million and income from continuing operations was $96 million, or $0.42 per diluted share. Excluding nonrecurring items, adjusted operating income increased $40 million to $179 million and adjusted income from continuing operations increased $38 million to $118 million, or $0.52 per diluted share. The adjusted tax rate for the quarter was 26.2 percent.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D), restructuring and acquisition integration charges and loss on the sale of assets totaled $351 million, or 36 percent of total revenue. Excluding $30 million of nonrecurring items, adjusted operating expenses totaled $321 million, or 33 percent of total revenue. Adjusted SG&A expenses were $281 million and R&D investments totaled $40 million.

Critical Care TechnologiesRevenue for the Critical Care Technologies segment increased 7 percent to $767 million driven by Infusion product sales, including core growth and a contribution from the May 2010 acquisition of Medegen and an increase in Dispensing sales. These increases were offset by an expected decrease in Respiratory sales due to a weak post-H1N1 environment. Segment profit increased 29 percent to $137 million, and adjusted segment profit increased 24 percent to $153 million.

Medical Technologies and ServicesRevenue for the Medical Technologies and Services segment decreased 8 percent to $197 million, driven by the loss of revenue from the company's April 2011 divestiture of the OnSite Services business, as well as the May 2010 divestiture of the Research Services business, which offset increased sales from the Infection Prevention and Medical Specialties businesses. Net of these divestitures, period-over-period revenue growth would have been 5 percent. Segment profit increased 75 percent to $14 million due to margin expansion and strong expense controls, and adjusted segment profit increased 63 percent to $26 million.

Fiscal 2011 ResultsRevenue for fiscal 2011 increased 2 percent to $3.53 billion. Operating income increased to $496 million and income from continuing operations increased to $291 million, or $1.29 per diluted share. Excluding nonrecurring items, adjusted operating income increased $87 million to $602 million and adjusted income from continuing operations increased $70 million to $371 million, or $1.65 per diluted share.

Operating expenses totaled $1.31 billion or 37 percent of total revenue. Excluding $106 million of nonrecurring items, adjusted operating expenses totaled $1.2 billion, or 34 percent of total revenue. Adjusted SG&A expenses were $1.05 billion, and R&D investments totaled $155 million.

Critical Care TechnologiesRevenue for the Critical Care Technologies segment increased 3 percent to $2.73 billion. Segment profit increased 10 percent to $434 million, and adjusted segment profit increased 14 percent to $511 million.

Medical Technologies and ServicesRevenue for the Medical Technologies and Services segment decreased 4 percent to $799 million. Net of the OnSite Services and Research Services divestitures, year-over-year revenue growth would have been 7 percent. Segment profit increased 17 percent to $49 million, and adjusted segment profit increased 40 percent to $91 million.

Fiscal 2012 Outlook For the fiscal year ending June 30, 2012, CareFusion expects revenues to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion. Adjusted diluted earnings per share for fiscal 2012 are expected to be in the range of $1.80 to $1.90. The guidance is based on an assumed diluted weighted average outstanding share count of approximately 226 million.

Conference CallCareFusion will host a conference call today at 2 p.m. PDT (5 p.m. EDT) to discuss earnings results for the fourth quarter and fiscal 2011.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (866) 783-2139 within the U.S. or (857) 350-1598 from outside the U.S., and use the access code 69553494. A replay of the conference call will be available from 5 p.m. PDT (8 p.m. EDT) on Aug. 8 through 8:59 p.m. PDT (11:59 p.m. EDT) on Aug. 15 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 Internationally and using the access code 40211522.

About CareFusion CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AirLife™, AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined™ services for data mining surveillance, V. Mueller® and Snowden-Pencer® surgical instruments and Nicolet® diagnostic products. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

Use of Non-GAAP Financial Measures by CareFusion CorporationThis CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows:  "adjusted operating expenses", "adjusted SG&A expenses" and "adjusted operating income", which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring (gain)/loss on the sale of assets;  "adjusted income from continuing operations", "adjusted diluted earnings per share from continuing operations" and "adjusted tax rate", which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring (gain)/loss on the sale of assets, and nonrecurring tax items; and "adjusted segment profit", which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

The most directly comparable measure for these non-GAAP financial measures are operating expenses, SG&A expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarter and fiscal year periods ended June 30, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

In addition, CareFusion presents the non-GAAP financial measure "adjusted diluted earnings per share" on a forward-looking basis. The most directly comparable forward-looking GAAP measure for the company is diluted earnings per share. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on Aug. 8, 2011.

Cautions Concerning Forward-looking StatementsThe CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Aug. 8, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)Quarter EndedJune 30,(in millions, except per share amounts)20112010Revenue$

964

$

930Cost of Products Sold464477Gross Margin500453Selling, General and Administrative Expenses298287Research and Development Expenses4044Restructuring and Acquisition Integration Charges118(Gain)/Loss on the Sale of Assets2(12)Operating Income149126Interest Expense and Other, Net 1919Income Before Income Tax130107Provision for Income Tax3460Income from Continuing Operations9647Discontinued OperationsLoss from the Disposal of Discontinued Businesses, Net of Tax(5)-Income (Loss) from the Operations of Discontinued Businesses, Net of Tax(6)5Income (Loss) from Discontinued Operations, Net of Tax(11)5Net Income$

85

$

52Per Share Amounts: 1Basic Earnings (Loss) per Common Share:Continuing Operations$

0.43

$

0.21Discontinued Operations$

(0.05)

$

0.02Basic Earnings per Common Share$

0.38

$

0.24Diluted Earnings (Loss) per Common Share:Continuing Operations$

0.42

$

0.21Discontinued Operations$

(0.05)

$

0.02Diluted Earnings per Common Share$

0.37

$

0.23Weighted-Average Number of Common Shares Outstanding:Basic223.4221.8Diluted 226.5224.0____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented. CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)Fiscal Year EndedJune 30,(in millions, except per share amounts)20112010Revenue$

3,528

$

3,472Cost of Products Sold1,7231,740Gross Margin1,8051,732Selling, General and Administrative Expenses1,1031,121Research and Development Expenses155159Restructuring and Acquisition Integration Charges6415Gain on the Sale of Assets(13)(12)Operating Income496449Interest Expense and Other, Net 81108Income Before Income Tax415341Provision for Income Tax124183Income from Continuing Operations291158Discontinued OperationsLoss from the Disposal of Discontinued Businesses, Net of Tax(45)(8)Income (Loss) from the Operations of Discontinued Businesses, Net of Tax(2)44Income (Loss) from Discontinued Operations, Net of Tax(47)36Net Income$

244

$

194Per Share Amounts: 1Basic Earnings (Loss) per Common Share:Continuing Operations$

1.31

$

0.71Discontinued Operations$

(0.21)

$

0.16Basic Earnings per Common Share$

1.09

$

0.88Diluted Earnings (Loss) per Common Share:Continuing Operations$

1.29

$

0.71Discontinued Operations$

(0.21)

$

0.16Diluted Earnings per Common Share$

1.08

$

0.87Weighted-Average Number of Common Shares Outstanding:Basic222.8221.5Diluted 225.1223.0____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended June 30, 2011DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations 1Items 2Adjusted 3Revenue 4$

964

$

-

$

-

$

964Cost of Products Sold464--464Gross Margin500--500Selling, General and Administrative Expenses298-(17)281Research and Development Expenses40--40Restructuring and Acquisition Integration Charges11-(11)-Loss on the Sale of Assets2-(2)-Operating Income149-30179Interest Expense and Other, Net 19--19Income Before Income Tax130-30160Provision for Income Tax34-842Income from Continuing Operations96-22118Discontinued OperationsLoss from the Disposal of Discontinued Businesses, Net of Tax(5)5--Loss from the Operations of Discontinued Businesses, Net of Tax(6)6--Loss from Discontinued Operations, Net of Tax(11)11--Net Income

$

85

$

11

$

22

$

118Per Share Amounts: 5Basic Earnings per Common Share

$

0.38

$

0.05

$

0.10

$

0.52Diluted Earnings per Common Share

$

0.37

$

0.05

$

0.10

$

0.52Weighted-Average Number of Common Shares Outstanding:Basic223.4223.4223.4223.4Diluted 226.5226.5226.5226.5Effective Tax Rate26.4%n/a25.7%26.2%____________1Reflects the impact of the divestiture of the International Surgical Products (ISP) business.2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring loss on the sale of assets and nonrecurring tax items.  3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Revenues increased $34 million for the quarter ended June 30, 2011 compared to 2010, or a $18 million increase on a constant currency basis.5Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Fiscal Year Ended June 30, 2011DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations 1Items 2Adjusted 3Revenue 4$

3,528

$

-

$

-

$

3,528Cost of Products Sold1,723--1,723Gross Margin1,805--1,805Selling, General and Administrative Expenses1,103-(55)1,048Research and Development Expenses155--155Restructuring and Acquisition Integration Charges64-(64)-Gain on the Sale of Assets(13)-13-Operating Income496-106602Interest Expense and Other, Net 81--81Income Before Income Tax415-106521Provision for Income Tax124-26150Income from Continuing Operations291-80371Discontinued OperationsLoss from the Disposal of Discontinued Businesses, Net of Tax(45)45--Loss from the Operations of Discontinued Businesses, Net of Tax(2)2--Loss from Discontinued Operations, Net of Tax(47)47--Net Income

$

244

$

47

$

80

$

371Per Share Amounts: 5Basic Earnings per Common Share

$

1.09

$

0.21

$

0.36

$

1.66Diluted Earnings per Common Share

$

1.08

$

0.21

$

0.36

$

1.65Weighted-Average Number of Common Shares Outstanding:Basic222.8222.8222.8222.8Diluted225.1225.1225.1225.1Effective Tax Rate30.0%n/a24.3%28.8%____________1Reflects the impact of the divestiture of the International Surgical Products (ISP) business.2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets and nonrecurring tax items.  3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Revenues increased $56 million for the fiscal year ended June 30, 2011 compared to 2010, or a $44 million increase on a constant currency basis.5Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended June 30, 2010DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations 1Items 2Adjusted 3Revenue $

930

$

-

$

-

$

930Cost of Products Sold477--477Gross Margin453--453Selling, General and Administrative Expenses287-(17)270Research and Development Expenses44--44Restructuring and Acquisition Integration Charges 8-(8)-Gain on the Sale of Assets(12)-12-Operating Income126-13139Interest Expense and Other, Net 19--19Income Before Income Tax107-13120Provision for Income Tax60-(20)40Income from Continuing Operations47-3380Discontinued OperationsIncome from the Operations of Discontinued Businesses, Net of Tax5(5)--Income from Discontinued Operations, Net of Tax5(5)--Net Income

$

52

$

(5)

$

33

$

80Per Share Amounts: 4Basic Earnings per Common Share

$

0.24

$

(0.02)

$

0.15

$

0.36Diluted Earnings per Common Share

$

0.23

$

(0.02)

$

0.15

$

0.36Weighted-Average Number of Common Shares Outstanding:Basic221.8221.8221.8221.8Diluted 224.0224.0224.0224.0Effective Tax Rate55.8%n/a(164.7)%33.0%____________1Reflects the impact of the divestiture of the International Surgical Products (ISP) business.2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets, and nonrecurring tax items. 3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Fiscal Year Ended June 30, 2010DiscontinuedNonrecurring(in millions, except per common share amounts)GAAP Operations 1Items 2Adjusted 3Revenue $

3,472

$

-

$

-

$

3,472Cost of Products Sold1,740--1,740Gross Margin1,732--1,732Selling, General and Administrative Expenses1,121-(63)1,058Research and Development Expenses159--159Restructuring and Acquisition Integration Charges 15-(15)-Gain on the Sale of Assets(12)-12-Operating Income449-66515Interest Expense and Other, Net 108-(22)86Income Before Income Tax341-88429Provision for Income Tax183-(55)128Income from Continuing Operations158-143301Discontinued OperationsLoss from the Disposal of Discontinued Businesses, Net of Tax(8)8--Income from the Operations of Discontinued Businesses, Net of Tax44(44)--Income from Discontinued Operations, Net of Tax36(36)--Net Income

$

194

$

(36)

$

143

$

301Per Share Amounts: 4Basic Earnings per Common Share

$

0.88

$

(0.16)

$

0.65

$

1.36Diluted Earnings per Common Share

$

0.87

$

(0.16)

$

0.64

$

1.35Weighted-Average Number of Common Shares Outstanding:Basic221.5221.5221.5221.5Diluted223.0223.0223.0223.0Effective Tax Rate53.7%n/a(63.1)%29.8%____________1Reflects the impact of (a) removing certain businesses that manufacture and sell surgical and exam gloves, surgical drapes and apparel and fluid management products in the U.S. market that were previously part of the Clinical and Medical Products segment of Cardinal Health and were retained by Cardinal Health upon the spinoff, (b) the divestiture of the Company's audiology business and (c) the divestiture of the International Surgical Products (ISP) business.2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets, nonrecurring charges related to the bridge loan entered into in connection with the spinoff, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions and nonrecurring tax items associated with the other non-tax adjustments.3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended June 30, 2011Nonrecurring(in millions)GAAP Items 1Adjusted 2Critical Care TechnologiesRevenue$

767-767Operating Income 313716153Medical Technologies and ServicesRevenue$

197-197Operating Income 3141226Fiscal Year Ended June 30, 2011Nonrecurring(in millions)GAAP Items 1Adjusted 2Critical Care TechnologiesRevenue$

2,729-2,729Operating Income443477511Medical Technologies and ServicesRevenue$

799-799Operating Income4494291Quarter Ended June 30, 2010Nonrecurring(in millions)GAAP Items 1Adjusted 2Critical Care TechnologiesRevenue$

716

$

-

$

716Operating Income510617123Medical Technologies and ServicesRevenue$

214

$

-

$

214Operating Income58816Fiscal Year Ended June 30, 2010Nonrecurring(in millions)GAAP Items 1Adjusted 2Critical Care TechnologiesRevenue$

2,644

$

-

$

2,644Operating Income539555450Medical Technologies and ServicesRevenue$

828

$

-

$

828Operating Income5422365____________1Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.2Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.3The $2 million loss on the sale of assets associated with the divestiture of our Research Services business has not been allocated to segment results for the quarter ended June 30, 2011.4The $13 million net gain on the sale of assets associated with the divestiture of our OnSite Services business ($15 million gain) and Research Services business ($2 million loss) has not been allocated to segment results for the fiscal year ended June 30, 2011.5The gain on the sale of assets associated with the divestiture of our Research Services business has not been allocated to segment results for the quarter and fiscal year ended June 30, 2010.
'/>"/>

SOURCE CareFusion Corp.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
2. CareFusion Will Host an Earnings Conference Call on Aug. 8 to Discuss the Results for the Fourth Quarter and Fiscal 2011
3. CareFusion to Acquire Pharmacy Automation Innovator Rowa
4. CareFusion Reports Third Quarter Rise in Revenue, Earnings
5. CareFusion Will Host an Earnings Conference Call on May 5 to Discuss the Results for the Third Quarter Fiscal 2011
6. CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste
7. CareFusion Announces Departure of Chief Operating Officer
8. CareFusion Completes Sale of Onsite Services Instrument Management and Repair Business
9. CareFusion Launches Innovative Vertebral Balloon That Gives Surgeons More Options to Treat Spinal Fractures
10. CareFusion Launches Compact Ventilator to Enhance Home-Based Patient Mobility
11. CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... CAMBRIDGE, England , May 25, 2016 /PRNewswire/ ... genomics company employing the precision of circulating tumour ... oncology, today announces the appointment of Professor ... will provide medical leadership across the clinical development ... that Inivata,s products help deliver significant improvements in ...
Breaking Medicine Technology:
(Date:5/28/2016)... California (PRWEB) , ... May 28, 2016 , ... "Color ... to drag and drop a preset onto their media," said Christina Austin - CEO ... Film Studios, editors can quickly and easily add stylish color grades to their footage. ...
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... PALMYRA, Wis. (PRWEB) , ... May 27, 2016 ... ... over $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this ... She accepted her award on May 18 at the university’s Student Leadership Awards ...
Breaking Medicine News(10 mins):